Skip to main content

Table 3 Prognostic/predictive factors at univariate analysis

From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Predictive for survival

N

HR

95% CI

Median survival (months)

2-sided P value

AREG mRNA (25th percentile)

 

0.47

0.31-0.70

 

0.0002

High

124

  

29

 

Low

40

  

16

 

EREG mRNA (75th percentile)

 

0.45

0.28-0.72

 

0.0009

High

39

  

36

 

Low

117

  

23

 

BRAF

 

8.1

3.44-19.0

 

0.00005

Mutation

6

  

12

 

Wild type

208

  

28

 

KRAS codon 12

 

1.62

1.10-2.38

 

0.014

Mutation

44

  

19

 

Wild type

129

  

29

 

Predictive for Response

 

Odds Ratio for Response

95% CI

 

2-sided P

AREG mRNA at 25th percentile

 

1.59

0.67-3.77

 

0.29

High vs. Low

     

EREG mRNA at 75th percentile

 

2.26

1.04-4.91

 

0.04

High vs. Low